BD FocalPoint GS User Manual page 33

The following table indicates recommended screening action guidelines: (individual laboratory
policies may differ)
BD FocalPoint™
Situation
Slide Information
Any age, all patients
Abnormal ECC+ / ECC–
Cyclic Patient, ECC+
Cervix Intact
Cyclic Patient, ECC+
Cervix Intact
Cyclic Patient, ECC–
Cervix Intact
Post-menopausal ECC+
Any age, cervix ECC+
intact, Limited
Cellularity
Any age, cervix ECC+
intact and Organism
Hysterectomy ECC+
Any age, all patients Insufficient
Squamous
(see note below)
Any age, all patients
ECC+/ECC
Process Review Yellow screen
Re-Run Pink Screen
FOV
findings
ABNORMAL
NILM/ECC+
NILM/ECC–
NILM/ECC–
NILM,
Atrophy/
ECC –
NILM/ECC+/
Scant
cellularity
NILM/ECC–/
Scant
cellularity
NILM/Org/
ECC+
NILM/Org/
ECC –
NILM/ECC
No FOVs
No FOVs
–
Table 3-4 – Screening Action Guidelines
Summary Action
FOV plus Full Slide Review
FOV only
FOV with partial full slide review until
ECC confirmed
FOV only
Laboratory discretion- may include;
FOV only (ECC uncertain due to
atrophy) or FOV with partial full slide
review until ECC confirmed
FOV followed by cell count along circle
diameter to assess adequacy
FOV with partial full slide review until
ECC confirmed & cell count along circle
diameter to assess adequacy
FOV only
FOV with partial full slide review until
ECC confirmed
FOV only
–
Full Slide Review
Full Slide Review
Full Slide Review
Full Slide Review
Guided Screening
33